SCHEMBL2909443

SCHEMBL2909443

COc1ccc(C(NC2CCN(C(=O)OC(C)(C)C)CC2)c2cccnc2)cc1O[C@@H]1CCOC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 10/20 0.43
PDE4B Q07343 10/20 0.43
PDE4A P27815 8/20 0.43
PDE4C Q08493 7/20 0.43
GPR119 Q8TDV5 2/20 0.42
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP3A5 P20815 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
DYRK1A Q13627 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2907022 0.90 PDE4D (0.42) PDE4DPDE4BPDE4APDE4C
SCHEMBL2906904 0.87 GPR119 (0.41) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL2908927 0.87 GPR119 (0.41) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL2909446 0.78 PDE4D (0.45) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL22773259 0.76 GPR119 (0.51) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL22491593 0.76 GPR119 (0.51) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL2908928 0.72 GPR119 (0.42) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL8284801 0.70 GPR119 (0.40) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL13342937 0.70 CFTR (0.47) PDE4DPDE4BPDE4APDE4CGPR119
SCHEMBL3609935 0.70 CFTR (0.47) PDE4DPDE4BPDE4APDE4CGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP claimed
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
EP-1692109-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS Memory Pharmaceuticals Corporation (US) 2006-08-23 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed
WO-2005061458-A2 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARMACEUTICALS CORPORATION (US) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B PDE4D 6/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.